Pure Global

Quantitative procalcitonin (PCT) test kit - Vietnam Registration 2300878ĐKLH/BYT-HTTB

Access comprehensive regulatory information for Quantitative procalcitonin (PCT) test kit in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2300878ĐKLH/BYT-HTTB and manufactured by BIOMERIEUX SA.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
2300878ĐKLH/BYT-HTTB
Registration Details
Vietnam MOH Registration: 2300878ĐKLH/BYT-HTTB
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Quantitative procalcitonin (PCT) test kit
VN: Bộ xét nghiệm định lượng procalcitonin (PCT)
Risk Class TTBYT Loại C

Registration Details

2300878ĐKLH/BYT-HTTB

000.00.04.G18-220630-0015

VIDAS B.R.A.H.M.S PCT

30450

Company Information

FRANCE

Technical Details

VIDAS® B·R·A·H·M·S PCT™ is an automated test performed on the VIDAS® analyzer to detect human procalcitonin in serum or plasma (lithium heparin) samples by the ELFA (Enzyme-Linked Fluorescent Assay - Enzyme Linked Fluorescent Assay) technique. This test, combined with other test results and clinical assessments, is a valuable tool in the evaluation of critically ill patients on the first day of admission to the Intensive Care Unit (ICU), and in predicting the risk of severe sepsis and septic shock. Used in conjunction with other test results and clinical assessments, VIDAS® B·R·A·H·M·S PCT™ also supports the decision-making process for antibiotic therapy in patients with lower respiratory tract infections (LRTI), including community-acquired pneumonia, acute exacerbations of chronic obstructive pulmonary disease (COPD), and acute bronchitis.

Dates and Status

Sep 26, 2023